trending Market Intelligence /marketintelligence/en/news-insights/trending/HkjlpWjPKtQqyUMGIgG2CA2 content esgSubNav
In This List

ImmunoGen prices common stock offering


According to Market Intelligence, December 2022


Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Japan M&A By the Numbers: Q3 2022

ImmunoGen prices common stock offering

ImmunoGen Inc. priced an underwritten public offering of 14.5 million common shares at $6.50 apiece.

The company expects gross proceeds of about $94.3 million.

The company granted underwriters a 30-day option to buy up to an additional 2,175,000 common shares at the offering price.

The offering is expected to close by Oct. 11, subject to customary closing conditions.

ImmunoGen plans to use net proceeds to help fund its operations, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the offering, with Canaccord Genuity as sole co-manager.